Addition of a dopamine agonist, cabergoline, to a serotonin-noradrenalin reuptake inhibitor, milnacipran as a therapeutic option in the treatment of refractory depression: Two case reports

Clinical Neuropharmacology

Volumn 26, Issue 5, 2003, Pages 230-232

  Takahashi, Hitoshi ^a   Yoshida, Keizo ^a   Higuchi, Hisashi ^b   Shimizu, Tetsuo ^a   Inoue, Takeshi ^c   Koyama, Tsukasa ^c  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Omagari City Hospital   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cabergoline; Depression; Dopamine; Energy; Milnacipran

Indexed keywords

BROTIZOLAM; CABERGOLINE; CLOMIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUVOXAMINE; LITHIUM; MILNACIPRAN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; TRIAZOLAM;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DOPAMINE BRAIN LEVEL; ENERGY; FATIGUE; HUMAN; MALE; MOTIVATION; NEUROTRANSMISSION; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SWEATING; SYMPTOMATOLOGY; VISUAL IMPAIRMENT; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ERGOLINES; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 0141532974     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200309000-00005     Document Type: Article

References (12)

1. Tylee A, Gastpar M, Lepine JP, et al. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol. 1999;14:139-151.
2. Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiatry. 2002;63:7-8.
3. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):5-9.
4. Swindle R, Kroenke K, Braun L. Energy and improved workplace productivity in depression. In: Investigating in Health: The Social and Economic Benefits of Health Care Innovation, vol 14. Elsevier Science Ltd 2001:323-341.
5. Schmidt K, Nolte-Zenker B, Patzer J, et al. Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Pharmacopsychiatry. 2001;34:66-72.
6. Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians. 1999;111:22-34.
7. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57:449-454.
8. Inoue T, Tsuchiya K, Miura J, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry. 1996;40:151-153.
9. Izumi T, Inoue T, Kitagawa N, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord. 2000;61:127-132.
10. Perugi G, Toni C, Ruffolo G, et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001;34:137-141.
11. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry. 2000;12:137-140.
12. DeBattista C, Solvason HB, Breen JA, et al. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol. 2000;20:274-275.